고위험 자궁경부암의 수술 후 보조요법으로서 Paclitaxel과Carboplatin 동시 항암화학방사선요법의 효능과 안전성

키워드

참고문헌 (39)

1. Parkin DM, "Estimates of the worldwide incidence of 25 major cancers in 1990", 80, pp.827~841 (1999)
2. "한국 중앙 암 등록 사업 연례 보고서" (2003), 한국중앙암등록본부
3. "한국 부인암 등록사업 조사 보고서", 46, pp.1849~1887 (2003), 대한산부인과학회 종양분과위원회
4. DiSaia PJ, "Clinical gynecologic oncology" (1997), St. Louis: Mosby
5. Morrow CP, "Is pelvic radiation beneficial in the postoperative management of stage IB squamous cell carcinoma of the cervix with pelvic node metastasis treated by radical hysterectomy and pelvic lymphadenectomy?", 10, pp.105~110 (1983)
6. Alvarez RD, "Value of adjuvant whole-pelvis irradiation after Wertheim hysterectomy for early-stage squamous carcinoma of the cervix with pelvic lymph node metastasis:a matched control study", 34, pp.258~262 (1989)
7. Soper JT, "Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer", 37, pp.390~395 (1990)
8. Keys HM, "radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical cancer", 340, pp.1154~1161 (1999)
9. Whitney CW, "A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjuvant to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative paraaortic lymph nodes", 17, pp.1339~1348 (1999)
10. Bundy BN, "Concurrent cisplatin-based chemoradiation in locally advanced cervical cancer", 340, pp.1144~1153 (1999)
11. Morris M, "Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer. A randomized Radiation Therapy Oncology Group clinical trial", 340, pp.1137~1143 (1999)
12. III, "Cisplatin and 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive in high- risk early-stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy:Report of a phase III intergroup study", 72, pp.443~ (1999)
13. Bethesda, MD, "US Dept. of Health and Human Services. NCI Clinical Announcement. Public Health Service, National Institute of HealthNational Institute of Health" (1999)
14. Kurbacher CM, "The role of chemotherapy in invasive cancer of the cervix uteri:current standards and future prospects", 12, pp.787~795 (2001)
15. Vance RB, "The platinum compounds and paclitaxel in the management of carcinoma of the endometrium and the uterine cervix", 22(12), pp.67~72 (1995)
16. Blessing JA, "Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of cervix", 17, pp.761~766 (1999)
17. Sarris K, "Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix", 17, pp.761~766 (1999)
18. R.S. Go, "Review of comperative pharmacology and clinical activity of cisplatin and carboplatin", 17, pp.409~422 (1999)
19. "National Cancer Institute Cancer Therapy Evaluation Program: Common Toxicity Criteria, Version 2.0", pp.~2 (1998), http:
20. Evans AJ, "Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinomal cell lines", 34, pp.367~374 (1996)
21. Curtin JP, "Carboplatin as a radiation sensitizer in locally advanced cervical cancer:a pilot study", 65, pp.336~342 (1997)
22. Davey MW, "Paclitaxel sensitizes multidrug resistant cells to radiation", 7, pp.182~188 (1996)
23. Hu LJ, "Cytotoxic and cell-cycle effects of paclitaxel when used as single agent and in combination with ionizing radiation", 37, pp.885~895 (1997)
24. Conley B, "A pilot trial of paclitaxel carboplatin and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck", 24(2), pp.78~80 (1997)
25. Comella P, "Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer:A phase I study", 15, pp.1409~1417 (1997)
26. Rose PG, "Paclitaxel and cisplatin as first line therapy in recurrent or advanced squamous cell carcinoma of the cervix", 72, pp.463~ (1999)
27. Ghamande SA, "First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix-a phase II study", 75, pp.334~337 (1999)
28. Dowlati A, "Multi-institutional phase I", II trial of paclitaxel and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma, 2000, pp.18, 1202~1209
29. Spencer SA, "Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer:long-term follow-up of a phase I trial", 37, pp.189~199 (2002)
30. Johnson SW, "Pharmacology of cancer chemotherapy. In:Cancer: Principles and Practice of Oncology", pp.376~387 (1998), Lippincott
31. Newell DR, "Carboplatin dosage:prospective evaluation of a simple formula based on renal function", 7, pp.1748~1756 (1989)
32. Lacy CF, "Drug Information Handbook" (2001), Hudson: Lexi-comp
33. Kirwan JM, "Survival and recurrence after concomitant chemotherapy for cancer of the uterine cervix:a systemic review and meta-analysis", 358, pp.781~786 (2001)
34. Frezza P, "Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri", 11, pp.455~459 (2000)
35. Papadimitriou CA, "Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix", 17, pp.761~766 (1999)
36. Richter B, "Cisplatin", paclitaxel vs carboplatin, pp.1998, 17[DOI]
37. Bundy BN, "A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy:a Gynecologic Oncology Group Study", 73, pp.177~183 (1999)
38. Sakuragi N, "Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy", 81, pp.1144~1151 (2002)
39. Lu Y, "Surgically defined prognostic parameters in patients with early cervical carcinoma:A multivariatae analysis", 78, pp.1438~1446 (1996)

관련 논문AI추천